Conversely, multiplicity of substrates can be a challenge for targeted therapies. The other concerns are the therapeutic window and the selectivity between normal and cancer cells. Despite of these concerns, the attractive feature of APC/C as a potent drug target is that outcome of APC/C activity can be controlled by modulating either of the two adaptor proteins–FZR1 or CDC20. Here, FZR1 is linked to cancer.